Apitope starts new clinical trial of its investigational multiple sclerosis treatment

19-May-2010 - United Kingdom

Apitope announced the start of its second Phase I clinical trial of ATX-MS-1467, in patients with multiple sclerosis (MS).

ATX-MS-1467, an investigational peptide-based therapeutic derived from Apitope’s proprietary technology platform, has already completed successfully a Phase I clinical trial in six patients with secondary progressive MS (SPMS). This new Phase I study aims to build on the results from the initial study and investigates safety and proof-of-principle of ATX-MS-1467 in 40 patients with relapsing forms of MS (RMS). The clinical trial will be carried out at up to ten sites across the UK.

The primary end point of the trial is safety and tolerability but secondary end points are designed to provide proof of principle. ATX-MS-1467 will be administered either intra-dermally or sub-cutaneously once every two weeks for 16 weeks, with a further 24 weeks of follow up.

Apitope is developing ATX-MS-1467 with Merck Serono. Under the terms of the agreement between the two companies, Apitope is responsible for all Phase I development of ATX-MS-1467. Merck Serono will take over development of the compound at the beginning of Phase II clinical trials.

https://www.bionity.com/en/news/117759/apitope-starts-new-clinical-trial-of-its-investigational-multiple-sclerosis-treatment.html